Xenetic Biosciences (XBIO) Competitors $3.66 +0.01 (+0.27%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsShort InterestTrends XBIO vs. BOLT, BCTX, LSTA, IBIO, CMMB, LSB, SPRB, NRBO, PIRS, and UBXShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include Bolt Biotherapeutics (BOLT), BriaCell Therapeutics (BCTX), Lisata Therapeutics (LSTA), iBio (IBIO), Chemomab Therapeutics (CMMB), Lakeshore Biopharma (LSB), Spruce Biosciences (SPRB), NeuroBo Pharmaceuticals (NRBO), Pieris Pharmaceuticals (PIRS), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical preparations" industry. Xenetic Biosciences vs. Bolt Biotherapeutics BriaCell Therapeutics Lisata Therapeutics iBio Chemomab Therapeutics Lakeshore Biopharma Spruce Biosciences NeuroBo Pharmaceuticals Pieris Pharmaceuticals Unity Biotechnology Xenetic Biosciences (NASDAQ:XBIO) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations. Does the media prefer XBIO or BOLT? In the previous week, Bolt Biotherapeutics had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 6 mentions for Bolt Biotherapeutics and 3 mentions for Xenetic Biosciences. Bolt Biotherapeutics' average media sentiment score of 0.23 beat Xenetic Biosciences' score of -0.14 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Xenetic Biosciences Neutral Bolt Biotherapeutics Neutral Which has more volatility & risk, XBIO or BOLT? Xenetic Biosciences has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Does the MarketBeat Community favor XBIO or BOLT? Xenetic Biosciences received 94 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 67.97% of users gave Xenetic Biosciences an outperform vote while only 64.52% of users gave Bolt Biotherapeutics an outperform vote. CompanyUnderperformOutperformXenetic BiosciencesOutperform Votes17467.97% Underperform Votes8232.03% Bolt BiotherapeuticsOutperform Votes8064.52% Underperform Votes4435.48% Is XBIO or BOLT more profitable? Xenetic Biosciences has a net margin of -161.63% compared to Bolt Biotherapeutics' net margin of -665.56%. Xenetic Biosciences' return on equity of -47.21% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xenetic Biosciences-161.63% -47.21% -42.14% Bolt Biotherapeutics -665.56%-64.49%-45.74% Which has better valuation & earnings, XBIO or BOLT? Xenetic Biosciences has higher earnings, but lower revenue than Bolt Biotherapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenetic Biosciences$2.52M2.24-$4.14M-$2.66-1.38Bolt Biotherapeutics$11.17M2.13-$69.20M-$1.71-0.36 Do insiders & institutionals have more ownership in XBIO or BOLT? 15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 14.7% of Xenetic Biosciences shares are held by company insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer XBIO or BOLT? Bolt Biotherapeutics has a consensus target price of $3.50, suggesting a potential upside of 462.34%. Given Bolt Biotherapeutics' higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryXenetic Biosciences and Bolt Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.64M$7.03B$5.37B$8.88BDividend YieldN/A8.03%5.06%4.03%P/E Ratio-1.3811.50127.4017.46Price / Sales2.24347.551,258.8592.75Price / CashN/A49.2239.3636.42Price / Book0.589.076.285.86Net Income-$4.14M$154.14M$119.59M$225.15M7 Day Performance-4.69%-2.23%-1.08%-0.90%1 Month Performance-1.21%7.49%3.63%3.70%1 Year Performance16.19%37.73%36.55%26.40% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences1.2681 of 5 stars$3.66+0.3%N/A+25.9%$5.64M$2.52M-1.384Earnings ReportAnalyst RevisionNews CoverageBOLTBolt Biotherapeutics3.683 of 5 stars$0.64-1.5%N/A-37.0%$24.33M$7.88M-0.37100Earnings ReportAnalyst ForecastShort Interest ↓BCTXBriaCell Therapeutics2.6645 of 5 stars$0.68-2.9%N/A-84.8%$24.26MN/A-0.5816LSTALisata Therapeutics3.3297 of 5 stars$2.90-0.3%N/A+30.4%$24.13MN/A-1.1330Short Interest ↓Gap DownIBIOiBio1.9306 of 5 stars$2.55-0.8%N/AN/A$23.26M$220,000.000.00100Gap DownCMMBChemomab Therapeutics2.7304 of 5 stars$1.57+6.8%N/A+216.4%$22.55MN/A-1.3820Short Interest ↑News CoverageGap UpLSBLakeshore Biopharma0.5669 of 5 stars$2.42+21.0%N/AN/A$22.52M$573.42M0.00773Short Interest ↑Gap UpHigh Trading VolumeSPRBSpruce Biosciences3.2731 of 5 stars$0.53flatN/A-52.7%$21.99M$9.57M-0.5220Earnings ReportAnalyst ForecastShort Interest ↓News CoverageNRBONeuroBo Pharmaceuticals3.211 of 5 stars$2.67-4.6%N/A-27.1%$21.95MN/A0.008Short Interest ↓News CoveragePIRSPieris Pharmaceuticals2.5379 of 5 stars$15.97-5.1%N/A-16.1%$21.08M$42.81M-0.85140Analyst UpgradeUBXUnity Biotechnology4.1431 of 5 stars$1.25+6.8%N/A-24.7%$21.06M$240,000.00-0.9560Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies BOLT Competitors BCTX Competitors LSTA Competitors IBIO Competitors CMMB Competitors LSB Competitors SPRB Competitors NRBO Competitors PIRS Competitors UBX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XBIO) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XBIO Stock Alerts